Developer docs
API playgroundTry for free, no card

Search company profiles

Osheru

Full company profile

uuid0003bv6

Namestring
Osheru
Legal namestring
Osheru LLC
Websiteurl
ziplyft.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Osheru is a Bend, Oregon-based private medical device company founded in 2020/2021 by Drs. Patty and Knute Buehler. The company develops and commercializes the Ziplyft device, an FDA Class I, 510(k) exempt medical device that uses the proprietary Compression Skin Contouring (CoCo) platform technology to enable sutureless, bloodless upper eyelid lifts (blepharoplasty). The device applies controlled tissue compression to achieve hemostasis and fuse tissue edges so that a guarded blade can excise redundant skin and closure can be achieved with medical adhesive rather than sutures, cautery, or IV sedation. Procedures are performed in-office under local anesthesia in approximately 10 minutes, with recovery reported in 5-7 days versus 2-3 weeks for traditional blepharoplasty.

The product portfolio is centered on Ziplyft and the underlying CoCo platform, with stated extensibility to lower lids, brow, chin, neck, and broader facial contouring. Osheru has built a medical advisory board of five key opinion leaders and, as of 2026, reports more than 142 procedures performed across 8 surgeons in clinical and early-adoption settings. The company has secured multiple industry recognitions including the 2022 Bend Venture Conference early-stage award and back-to-back Eyecelerator wins at ASCRS in 2023 and 2024.

Osheru generates revenue primarily through direct hardware sales of Ziplyft device and procedure kits to certified ophthalmologists, oculoplastic surgeons, and aesthetic practitioners via its e-commerce platform (products.ziplyft.com), supplemented by practitioner certification and training revenue. Pricing is described as comparable to traditional blepharoplasty but is quote-based and not publicly disclosed. Distribution is direct-to-surgeon, US-and-Canada focused, with a Medical Advisory Board functioning as the primary peer-referral channel. Capital to date totals approximately $4.95M, comprising a $4.7M seed round in July 2024 led by Nike co-founder Phil Knight with participation from Business Oregon, SOPHINCAP, and other family offices, plus a $250,000 SSBCI-backed investment from Elevate Capital in January 2026.

Short descriptiontext

Osheru is a Bend, Oregon-based private medical device company that develops the FDA Class I Ziplyft device, using its patented Compression Skin Contouring (CoCo) platform to enable sutureless, bloodless, in-office upper eyelid lifts for ophthalmologists, oculoplastic surgeons, and aesthetic practitioners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBend, United States
HQ citystring
Bend
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical device manufacturing, ophthalmic surgical devices, blepharoplasty devices, minimally invasive aesthetics, compression skin contouring
Industry1 code
PRIMARYHLAHAJAL
Oculoplastics & Lacrimal Surgical Devices (Ptosis/Orbital Tools, DCR/Lacrimal Stents, Facial Implants)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Ophthalmic Goods3851
Product category
Ophthalmic Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Ziplyft Device and Kit Sales
TypeHardware Sales
Description

Sale of medical devices and clinical procedure kits to certified ophthalmologists, oculoplastic surgeons, and aesthetic practitioners for in-office blepharoplasty procedures. Kits include all necessary procedural tools including the Ziplyft clamp device and medical adhesive.

ziplyft.com
2Practitioner Certification and Training
TypeProfessional Services
Description

Revenue from training programs, certification modules, and ongoing professional support for practitioners adopting CoCo and Ziplyft procedures. Training includes video instruction, hands-on practice, and ongoing support.

ziplyft.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Ziplyft™
Description

FDA Class I medical device for compression skin contouring (CoCo) enabling sutureless, bloodless upper eyelid lifts. First-in-class blepharoplasty device.

ziplyft.com
+2 more records
Core offering1 text field

Osheru manufactures and sells the Ziplyft device, an FDA Class I, 510(k) exempt medical instrument that uses its patented Compression Skin Contouring (CoCo) technology to perform bloodless, sutureless upper eyelid lifts in-office under local anesthesia in approximately 10 minutes. The company ships Ziplyft kits directly to certified ophthalmologists and oculoplastic surgeons and pairs device sales with mandatory practitioner certification and clinical training programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 142+ patients treated with Ziplyft as of 2026
+5 more records
Product overview1 text field

Osheru is a medical device company with a unified product portfolio centered on its Ziplyft device and the proprietary Compression Skin Contouring (CoCo) technology platform. Ziplyft is an FDA Class I, 510(k) exempt medical device for upper eyelid rejuvenation using blepharoplasty; it is the first compression skin contouring (CoCo) device enabling sutureless, bloodless eyelid lifts performed in-office under local anesthesia in approximately 10 minutes. CoCo serves as the core technology platform, with extensibility planned for lower lids, brow, chin, neck, and facial contouring applications.

Product and service2 records
1Ziplyft Device
CategoryOphthalmic Surgical Devices
Description

FDA Class I, 510(k) exempt medical device that uses Compression Skin Contouring (CoCo) technology to perform bloodless, sutureless upper eyelid lifts in-office under local anesthesia in approximately 10 minutes. Sold as a device kit to certified ophthalmologists and oculoplastic surgeons for cosmetic and functional blepharoplasty procedures.

2Practitioner Certification and Training Program
CategoryClinical Training Services
Description

Required certification, video instruction, hands-on practice, and ongoing support program that surgeons must complete before purchasing Ziplyft device kits. Includes clinical training on the CoCo and MILT procedural methods for upper eyelid lifts.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Lumenis is a global leader in energy-based medical and aesthetic devices, with strong ophthalmic and aesthetic surgery franchises. Comparable to Osheru as a broader incumbent operating in overlapping ophthalmic/aesthetic device categories that could expand into compression or mechanical blepharoplasty solutions.

TypeBroad incumbent
Description

Cynosure develops laser, light-based, and energy-based aesthetic platforms sold to plastic surgeons, dermatologists, and aesthetic practices. Comparable to Osheru as a larger incumbent addressing the same physician customer base seeking high-throughput in-office aesthetic procedures.

3Sciton
TypeDirect peer
Description

Sciton manufactures laser and light-based aesthetic and surgical platforms used in facial rejuvenation procedures including around the eyes. Comparable to Osheru in its focus on physician-channel aesthetic devices that improve procedure efficiency and recovery for cosmetic surgeons.

TypeBroad incumbent
Description

Alma Lasers is a global provider of aesthetic and surgical laser, light, RF, and ultrasound platforms for the medical aesthetics market. Comparable to Osheru as a broader incumbent offering multiple in-office aesthetic device solutions that compete for the same physician capital expenditure budgets.

TypeBroad incumbent
Description

Alcon is one of the largest global ophthalmic device and surgical companies, with deep relationships among cataract, refractive, and oculoplastic surgeons. Comparable to Osheru as a broad ophthalmic incumbent whose surgeon customer base is identical to Ziplyft's and who could launch competing eyelid surgery devices.

TypeDirect peer
Description

InMode develops minimally invasive aesthetic medical devices, including RF-based technologies applied to facial and periocular rejuvenation. Comparable to Osheru as a device-driven company targeting aesthetic surgeons and ophthalmologists seeking less invasive, in-office procedures.

TypeBroad incumbent
Description

Cutera manufactures laser and energy-based aesthetic systems for face and body treatments sold through medical aesthetic channels. Comparable to Osheru as an established aesthetics-device incumbent whose customer base (aesthetic physicians and practices) overlaps with Ziplyft's target surgeon population.

TypeDirect peer
Description

LightScalpel makes a CO2 laser system specifically marketed for blepharoplasty and eyelid surgery in office-based settings. A direct procedural-area peer to Ziplyft as both target oculoplastic and ophthalmic surgeons performing eyelid lifts with technology designed to improve patient outcomes.

TypeEmerging player
Description

Cytrellis is an early-stage aesthetics device company developing minimally invasive skin removal technologies for facial rejuvenation. Comparable to Osheru as a similarly staged emerging player pursuing novel, in-office aesthetic procedures targeting physician practices, with potential overlap in facial rejuvenation indications.

TypeBroad incumbent
Description

Bausch + Lomb is a global ophthalmic company spanning surgical, vision care, and ophthalmic pharmaceuticals with extensive surgeon relationships. Comparable to Osheru as a broad incumbent in the ophthalmic surgical space that could leverage scale to compete in oculoplastic and eyelid surgery device categories.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Osheru

Ophthalmic Medical Devicesziplyft.com

Osheru is a Bend, Oregon-based private medical device company that develops the FDA Class I Ziplyft device, using its patented Compression Skin Contouring (CoCo) platform to enable sutureless, bloodless, in-office upper eyelid lifts for ophthalmologists, oculoplastic surgeons, and aesthetic practitioners.

What Osheru does

Osheru is a Bend, Oregon-based private medical device company founded in 2020/2021 by Drs. Patty and Knute Buehler. The company develops and commercializes the Ziplyft device, an FDA Class I, 510(k) exempt medical device that uses the proprietary Compression Skin Contouring (CoCo) platform technology to enable sutureless, bloodless upper eyelid lifts (blepharoplasty). The device applies controlled tissue compression to achieve hemostasis and fuse tissue edges so that a guarded blade can excise redundant skin and closure can be achieved with medical adhesive rather than sutures, cautery, or IV sedation. Procedures are performed in-office under local anesthesia in approximately 10 minutes, with recovery reported in 5-7 days versus 2-3 weeks for traditional blepharoplasty.

The product portfolio is centered on Ziplyft and the underlying CoCo platform, with stated extensibility to lower lids, brow, chin, neck, and broader facial contouring. Osheru has built a medical advisory board of five key opinion leaders and, as of 2026, reports more than 142 procedures performed across 8 surgeons in clinical and early-adoption settings. The company has secured multiple industry recognitions including the 2022 Bend Venture Conference early-stage award and back-to-back Eyecelerator wins at ASCRS in 2023 and 2024.

Osheru generates revenue primarily through direct hardware sales of Ziplyft device and procedure kits to certified ophthalmologists, oculoplastic surgeons, and aesthetic practitioners via its e-commerce platform (products.ziplyft.com), supplemented by practitioner certification and training revenue. Pricing is described as comparable to traditional blepharoplasty but is quote-based and not publicly disclosed. Distribution is direct-to-surgeon, US-and-Canada focused, with a Medical Advisory Board functioning as the primary peer-referral channel. Capital to date totals approximately $4.95M, comprising a $4.7M seed round in July 2024 led by Nike co-founder Phil Knight with participation from Business Oregon, SOPHINCAP, and other family offices, plus a $250,000 SSBCI-backed investment from Elevate Capital in January 2026.

Osheru firmographics

Firmographics
Name
Osheru
Legal name
Osheru LLC
Website
https://ziplyft.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Osheru is a Bend, Oregon-based private medical device company that develops the FDA Class I Ziplyft device, using its patented Compression Skin Contouring (CoCo) platform to enable sutureless, bloodless, in-office upper eyelid lifts for ophthalmologists, oculoplastic surgeons, and aesthetic practitioners.
Ownership category
akta.pro rank

Osheru industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAJAL
Oculoplastics & Lacrimal Surgical Devices (Ptosis/Orbital Tools, DCR/Lacrimal Stents, Facial Implants)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Medical device manufacturing
  • Ophthalmic surgical devices
  • Blepharoplasty devices
  • Minimally invasive aesthetics
  • Compression skin contouring

Where Osheru is headquartered

Location

Headquarters

HQ city
Bend
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Osheru business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D

Revenue model

  1. Ziplyft Device and Kit Sales: Sale of medical devices and clinical procedure kits to certified ophthalmologists, oculoplastic surgeons, and aesthetic practitioners for in-office blepharoplasty procedures. Kits include all necessary procedural tools including the Ziplyft clamp device and medical adhesive.
  2. Practitioner Certification and Training: Revenue from training programs, certification modules, and ongoing professional support for practitioners adopting CoCo and Ziplyft procedures. Training includes video instruction, hands-on practice, and ongoing support.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Osheru product offering

Product offering

Core offering

Osheru manufactures and sells the Ziplyft device, an FDA Class I, 510(k) exempt medical instrument that uses its patented Compression Skin Contouring (CoCo) technology to perform bloodless, sutureless upper eyelid lifts in-office under local anesthesia in approximately 10 minutes. The company ships Ziplyft kits directly to certified ophthalmologists and oculoplastic surgeons and pairs device sales with mandatory practitioner certification and clinical training programs.

Product overview

Osheru is a medical device company with a unified product portfolio centered on its Ziplyft device and the proprietary Compression Skin Contouring (CoCo) technology platform. Ziplyft is an FDA Class I, 510(k) exempt medical device for upper eyelid rejuvenation using blepharoplasty; it is the first compression skin contouring (CoCo) device enabling sutureless, bloodless eyelid lifts performed in-office under local anesthesia in approximately 10 minutes. CoCo serves as the core technology platform, with extensibility planned for lower lids, brow, chin, neck, and facial contouring applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Ziplyft™: FDA Class I medical device for compression skin contouring (CoCo) enabling sutureless, bloodless upper eyelid lifts. First-in-class blepharoplasty device.
  • CoCo (Compression Skin Contouring)
  • MILT (Minimally Invasive Lid Treatment)

Products and services

  • Ziplyft Device FDA Class I, 510(k) exempt medical device that uses Compression Skin Contouring (CoCo) technology to perform bloodless, sutureless upper eyelid lifts in-office under local anesthesia in approximately 10 minutes. Sold as a device kit to certified ophthalmologists and oculoplastic surgeons for cosmetic and functional blepharoplasty procedures.
  • Practitioner Certification and Training Program Required certification, video instruction, hands-on practice, and ongoing support program that surgeons must complete before purchasing Ziplyft device kits. Includes clinical training on the CoCo and MILT procedural methods for upper eyelid lifts.

Quantifiable outcome

  • 142+ patients treated with Ziplyft as of 2026
  • +5 more outcomes

Companies that use Osheru

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles1 record

Osheru technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Osheru partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Osheru competitors and assessment

Company assessment

Broad incumbents

  • Lumenis: Lumenis is a global leader in energy-based medical and aesthetic devices, with strong ophthalmic and aesthetic surgery franchises. Comparable to Osheru as a broader incumbent operating in overlapping ophthalmic/aesthetic device categories that could expand into compression or mechanical blepharoplasty solutions.
  • Cynosure: Cynosure develops laser, light-based, and energy-based aesthetic platforms sold to plastic surgeons, dermatologists, and aesthetic practices. Comparable to Osheru as a larger incumbent addressing the same physician customer base seeking high-throughput in-office aesthetic procedures.
  • Alma Lasers: Alma Lasers is a global provider of aesthetic and surgical laser, light, RF, and ultrasound platforms for the medical aesthetics market. Comparable to Osheru as a broader incumbent offering multiple in-office aesthetic device solutions that compete for the same physician capital expenditure budgets.
  • Alcon: Alcon is one of the largest global ophthalmic device and surgical companies, with deep relationships among cataract, refractive, and oculoplastic surgeons. Comparable to Osheru as a broad ophthalmic incumbent whose surgeon customer base is identical to Ziplyft's and who could launch competing eyelid surgery devices.
  • Cutera: Cutera manufactures laser and energy-based aesthetic systems for face and body treatments sold through medical aesthetic channels. Comparable to Osheru as an established aesthetics-device incumbent whose customer base (aesthetic physicians and practices) overlaps with Ziplyft's target surgeon population.
  • Bausch + Lomb: Bausch + Lomb is a global ophthalmic company spanning surgical, vision care, and ophthalmic pharmaceuticals with extensive surgeon relationships. Comparable to Osheru as a broad incumbent in the ophthalmic surgical space that could leverage scale to compete in oculoplastic and eyelid surgery device categories.

Direct peers

  • Sciton: Sciton manufactures laser and light-based aesthetic and surgical platforms used in facial rejuvenation procedures including around the eyes. Comparable to Osheru in its focus on physician-channel aesthetic devices that improve procedure efficiency and recovery for cosmetic surgeons.
  • InMode: InMode develops minimally invasive aesthetic medical devices, including RF-based technologies applied to facial and periocular rejuvenation. Comparable to Osheru as a device-driven company targeting aesthetic surgeons and ophthalmologists seeking less invasive, in-office procedures.
  • LightScalpel: LightScalpel makes a CO2 laser system specifically marketed for blepharoplasty and eyelid surgery in office-based settings. A direct procedural-area peer to Ziplyft as both target oculoplastic and ophthalmic surgeons performing eyelid lifts with technology designed to improve patient outcomes.

Emerging players

  • Cytrellis Biosystems: Cytrellis is an early-stage aesthetics device company developing minimally invasive skin removal technologies for facial rejuvenation. Comparable to Osheru as a similarly staged emerging player pursuing novel, in-office aesthetic procedures targeting physician practices, with potential overlap in facial rejuvenation indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Osheru social profiles

Digital presence

Osheru compliance and trust

Trust signal

Compliance1 record

Osheru financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Osheru leadership team

Management profile

Number of profiles

Profiles3 records

Osheru funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Osheru M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Osheru

What does Osheru do?

Osheru manufactures and sells the Ziplyft device, an FDA Class I, 510(k) exempt medical instrument that uses its patented Compression Skin Contouring (CoCo) technology to perform bloodless, sutureless upper eyelid lifts in-office under local anesthesia in approximately 10 minutes. The company ships Ziplyft kits directly to certified ophthalmologists and oculoplastic surgeons and pairs device sales with mandatory practitioner certification and clinical training programs.

Is Osheru a public or private company?

Osheru is a private company. It is classified as venture growth investor backed and is currently operating.

When was Osheru founded?

Osheru was founded in 2021. It employs 11 to 50 people.

Where is Osheru based?

Osheru is headquartered in Bend, United States, in the North America region.

How does Osheru make money?

Two revenue lines are on record. Ziplyft Device and Kit Sales are the primary driver. The others are practitioner Certification and Training.

Who are Osheru's main competitors?

Broad incumbents on record are Lumenis, Cynosure, Alma Lasers, Alcon, Cutera and Bausch + Lomb. Direct peers are Sciton, InMode and LightScalpel. Cytrellis Biosystems is listed as an emerging player.

Does Osheru have an API?

No public API is recorded for Osheru.

What industry is Osheru in?

Osheru's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAL, Oculoplastics & Lacrimal Surgical Devices (Ptosis/Orbital Tools, DCR/Lacrimal Stents, Facial Implants). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mpo-magOsheru Secures Funding to Advance its Device for Eyelid SurgeryOsheru raised $4.7 million to advance its Ziplyft device for eyelid surgery, with investors including Nike co-founder Phil Knight. The company appointed John Garland as chief commercial officer and plans to commercialize the device in 2025.Business Wire BlogOsheru Secures $4.7 Million Seed Funding to Advance Revolutionary Ziplyft Device for Blepharoplasty SurgeryOsheru raised $4.7 million in seed funding led by Phil Knight and others to advance its Ziplyft device for blepharoplasty surgery. The company plans commercialization in 2025, targeting reduced recovery times and complications. The funding reflects investor confidence in the device's innovative approach.YahooOsheru Secures $4.7 Million Seed Funding to Advance Revolutionary Ziplyft Device for Blepharoplasty SurgeryOsheru raised $4.7 million in seed funding to advance its Ziplyft device for blepharoplasty surgery, with investment from Phil Knight and others. The company appointed John Garland as Chief Commercial Officer, targeting commercialization in 2025.FinSMEsOsheru Raises $4.7M in Seed FundingOsheru, a medical device company based in Bend, Oregon, raised $4.7 million in seed funding led by individuals and family offices, including Nike co-founder Phil Knight. The company intends to use the capital to accelerate the development and commercialization of its Ziplyft device for blepharoplasty surgery. Additionally, Osheru appointed John Garland as Chief Commercial Officer.